Navigation Links
ChromaDex Establishes a Blanket Purchase Agreement With the National Institutes of Health
Date:6/24/2009

The Blanket Purchase Agreement will expedite the purchasing process for groups within the National Institutes of Health.

IRVINE, Calif., June 24 /PRNewswire-FirstCall/ -- ChromaDex Corp., (OTC Bulletin Board: CDXC) a leader in phytochemical reference standards and contract research, announced today that the National Institutes of Health established a Blanket Purchase Agreement (BPA) with the Company. The Agreement covers all products and services offered by ChromaDex. This includes botanical reference materials, phytochemicals, bulk chemical production, analytical testing services, analytical method development, contract research, isolation of compounds, chemical synthesis and natural product libraries.

The BPA makes it easier for the various Institutes within NIH to do business with ChromaDex.

"We are honored to be recognized by the National Institutes of Health with the issuance of a Blanket Purchase Agreement to ChromaDex," said Frank Jaksch, co-founder and CEO of ChromaDex. "There is considerable work taking place at NIH in the areas of natural products, dietary supplements and alternative medicines. As a leader in this field, ChromaDex will be working closely with NIH to provide products and services to support their efforts."

About National Institutes of Health

NIH is the steward of medical and behavioral research for the Nation. Its mission is science in pursuit of fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to extend healthy life and reduce the burdens of illness and disability. Composed of 27 Institutes and Centers, the NIH provides leadership and financial support to researchers in every state and throughout the world. For over a century, the National Institutes of Health has played an important role in improving the health of the nation.

About ChromaDex

ChromaDex is a world leader in the development of Phytochemical and Botanical Reference Standards and the creation of associated intellectual property. ChromaDex is committed to sustainable "Green chemistry" and provides the dietary supplement, food, beverage, nutraceutical and cosmetic industries with the analytical tools and services to meet product regulatory, quality, efficacy and safety standards.

Forward-Looking Statements

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to ability to market, produce and sell the referenced ingredients, risks relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.


'/>"/>
SOURCE ChromaDex Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ChromaDex Reports 2009 Q1 Financial Results
2. ChromaDex Awarded Nutrition Business Journal Scientific Achievement
3. ChromaDex Partners With Cargill to Provide Global Quality Control Methods and Standards for Sweet Components of Stevia
4. ChromaDex Licenses Green Chemistry Technology to Manufacture a New Class of Super Fruit Compounds
5. Medical Study Establishes First-Ever Long-Term Benefits for Macular Degeneration Sufferers Using Macular Health Vitamin Supplement
6. Major New Report Establishes Effective Methods of Enhancing and Preserving Brain Power as We Age
7. DFG establishes nine new collaborative research centers
8. IBM Establishes Global Healthcare Centre of Excellence in La Gaude, France
9. Winner Medical Establishes Joint Venture With West China Hospital in Chengdu, China
10. Study in Nature Medicine establishes major new treatment target in diseased arteries
11. New Medical Study Establishes First-Ever Long-Term Benefits for Macular Degeneration Sufferers Using Macular Health Vitamin Supplement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2017)... ... June 24, 2017 , ... ... at the Sheraton Erie Bayfront and Erie Convention Center on June 8-10. ... exhibits, a student quiz bowl, award and scholarship presentations, and professional networking. ...
(Date:6/23/2017)... ... 23, 2017 , ... The Rhode Island Quality Institute (RIQI) ... and Dashboards, an innovative new service enabling healthcare providers to proactively coordinate care ... and Dashboards provide near real-time data about patients admitted to and/or discharged from ...
(Date:6/23/2017)... (PRWEB) , ... June 24, 2017 , ... Studies show ... significantly reduce the risk of visual loss in these patients. , But how often ... diet, or smoking cessation to patients at risk of or with early symptoms of ...
(Date:6/23/2017)... ... ... Everybody has their own personal preference when it comes to pornography. Some ... don't like it at all. FindaTopDoc took a look at what makes people attracted ... readers a taste of their deepest, darkest fantasies and has the ability to help ...
(Date:6/23/2017)... , ... June 23, 2017 , ... ... Cancer Conference from Sept. 18 to 20. , The two-day conference is focused ... with the goal of improving patients’ lives and eliminating racial breast cancer-related disparities. ...
Breaking Medicine News(10 mins):
(Date:6/13/2017)... June 13, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... announced that the U.S. Food and Drug Administration (FDA) has ... 2015 relating to its Zhejiang, China ... "The successful clearance of the Warning Letter related ... facility is a measure of the progress we have made ...
(Date:6/11/2017)... and Company (NYSE: LLY ) announced today ... an investigational treatment for the prevention of episodic and ... endpoints for galcanezumab compared to placebo at both studied ... REGAIN) will be presented today at the American Headache ... . "The detailed Phase 3 ...
(Date:6/9/2017)... PALO ALTO, Calif. , June 9, 2017 /PRNewswire/ ... medical device company focused on the design, manufacture, sale ... updated the market on the progress of its commercial ... AeroForm is now available in more than one hundred ... country. AeroForm offers a needle-free alternative ...
Breaking Medicine Technology: